| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H13ClN2S |
| Molecular Weight | 300.806 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NCC1=S)C3=CC=CC=C3
InChI
InChIKey=MWGWTOPCKLQYEU-UHFFFAOYSA-N
InChI=1S/C16H13ClN2S/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
| Molecular Formula | C16H13ClN2S |
| Molecular Weight | 300.806 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulazepam is a desmethylbenzodiazepine. It is the thioamide derivative of diazepam. It has sedative, muscle relaxant, hypnotic, anticonvulsant and anxiolytic properties like those of other benzodiazepines. Sulazepam in vivo in experimental animals undergoes enzymic desulfonation, demethylation, and [3C] hydroxylation, with the formation of basic metabolites: diazepam, desmethyldiazepam, and oxazepam.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
CBA mice weighing 18-22 g were given an
intraperitoneal injection of sulazepam, diazepam, desmethyldiazepam, and oxazepam (5 mg/kg) as an aqueous
emulsion with Tween-80.
Route of Administration:
Intraperitoneal
